Angiocrine Bioscience: Funding, Investors & Team (Sep 2026)
Angiocrine Bioscience is a private, clinical stage engineered cell therapy company harnessing the power of genetically modified human endothelial cells to regenerate tissues, restore function and rejuvenate patients with serious medical conditions. Our team is developing a pipeline of proprietary engineered endothelial cell (E-CEL® ) therapies for treating multiple life-threatening hemato-oncologic and immunologic conditions, as well as, regenerating tissues and organs that have been injured or damaged by diseases.
Angiocrine Bioscience has raised $73.1M across 2 funding rounds on record, the most recent an undisclosed round of $15.0M announced in Dec 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Angiocrine Bioscience Company Profile and Key Stats
Latest funding round on record: Dec 2022.
Angiocrine Bioscience Funding Rounds
Angiocrine Bioscience raised $58.1M in a Private Equity announced in Oct 2021.
1.2 years later, an undisclosed round of $15.0M was announced in Dec 2022.
Angiocrine Bioscience Founders and Leadership Team
No contact details are on record for this team yet.
Angiocrine Bioscience Funding Compared to Other Biotechnology Startups
Angiocrine Bioscience's latest round of $15.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Angiocrine Bioscience in Biotechnology and New York
Companies Similar to Angiocrine Bioscience
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Angiocrine Bioscience Funding FAQs
What does Angiocrine Bioscience do?
Angiocrine Bioscience is a private, clinical stage engineered cell therapy company harnessing the power of genetically modified human endothelial cells to regenerate tissues, restore function and rejuvenate patients with serious medical conditions. Our team is developing a pipeline of proprietary engineered endothelial cell (E-CEL® ) therapies for treating multiple life-threatening hemato-oncologic and immunologic conditions, as well as, regenerating tissues and organs that have been injured or damaged by diseases.
How much funding has Angiocrine Bioscience raised?
Angiocrine Bioscience has raised $73.1M across 2 rounds on record. The most recent is an undisclosed round of $15.0M announced in Dec 2022.
When did Angiocrine Bioscience last raise funding?
Angiocrine Bioscience's most recent funding round on record is an undisclosed round of $15.0M, announced in Dec 2022.
Who founded Angiocrine Bioscience?
FundedIQ lists Shahin Rafii (Founder) at Angiocrine Bioscience.
Who is the CEO of Angiocrine Bioscience?
Paul Finnegan is listed as CEO at Angiocrine Bioscience.
Where is Angiocrine Bioscience headquartered?
Angiocrine Bioscience is based in New York, United States.
How many employees does Angiocrine Bioscience have?
Angiocrine Bioscience is in the 11-50 employee band.
How does Angiocrine Bioscience's funding compare to other Biotechnology startups?
Angiocrine Bioscience's latest round of $15.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Angiocrine Bioscience Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Angiocrine Bioscience is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.